Results 221 to 230 of about 2,012,581 (282)

Reasonable Exceptions From Unreasonable Policies: Requiring Treatment Agreements for Long‐Term Opioid Therapy and Exemptions for Cancer and Terminal Illness

Bioethics, EarlyView.
ABSTRACT Since drug overdose deaths began increasing in the United States, policy makers and the medical community have developed tools to try to address the crisis. Opioid Treatment Agreements (OTAs) are one such tool which purportedly seek to promote shared decision‐making and informed consent with patients. OTAs are documents that clinicians present
Larisa Svirsky, Martin Fried, Minseo Kim, Sarah R. MacEwan, Nathan Richards, Patricia Zettler, Dana Howard   +6 more
wiley   +1 more source

The silent consequence of overdose: The case for brain injury‐informed opioid treatment

Addiction, EarlyView.
Nathaniel Day, Kym Kaufmann, Mauricio Garcia‐Barrera, Jitender Sareen, Daniel Vigo   +4 more
wiley   +1 more source

A scoping review of service user experiences of potential harm in early intervention in psychosis services in the UK

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives Early intervention in psychosis (EIP) services provide care for individuals experiencing first‐episode psychosis and are considered both clinically and cost‐effective. While many have positive experiences of EIP, there have also been reports of perceived harm.
Georgie Hudson, India Francis‐Crossley, Craig S. Mackie, Rachel Hiller, James B. Kirkbride, Claire Powell   +5 more
wiley   +1 more source

Gold‐standard evidence and best practice guidance for menstrual cycle‐informed clinical care: An overview for clinicians

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment.
Ellen R. Lambert, Louise N. Nolan, Katja M. Schmalenberger   +2 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Alcohol, Prescription Drug Misuse, Sexual Violence, and Dating Violence Among High School Youth. [PDF]

J Adolesc Health, 2018
Espelage DL, Davis JP, Basile KC, Rostad WL, Leemis RW.   +4 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Psychosocial risks of prescription drug misuse among U.S. racial/ethnic minorities: A systematic review. [PDF]

J Ethn Subst Abuse, 2019
Peteet BJ.
europepmc   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) CM de Lange   +26 more
wiley   +1 more source

Signal detection and characterisation of a novel drug–drug interaction between methadone and a synthetic cannabinoid receptor agonist

British Journal of Pharmacology, EarlyView.
Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock, Louise M. Hesketh, Hongwei Cheng, Shuoqi Chen, Simon Hudson, Graeme Henderson, Jules C. Hancox, Michael J. Shattock, Michael J. Curtis, Caroline S. Copeland   +9 more
wiley   +1 more source